Mechanism of Action and Clinical Impact of Ribociclib-Response

Affiliations

¹ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. dtripathy@mdanderson.org.
² Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center/Harvard Medical School, Boston, Massachusetts.
³ The Broad Institute and Dana-Farber Cancer Institute, Cambridge, Massachusetts.

Comment

Debu Tripathy et al. Clin Cancer Res. 2017.

. 2017 Sep 15;23(18):5658.

doi: 10.1158/1078-0432.CCR-17-1819.

¹ Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. dtripathy@mdanderson.org.
² Department of Hematology/Oncology, Massachusetts General Hospital Cancer Center/Harvard Medical School, Boston, Massachusetts.
³ The Broad Institute and Dana-Farber Cancer Institute, Cambridge, Massachusetts.

No abstract available

Comment on

Ribociclib (LEE011): Mechanism of Action and Clinical Impact of This Selective Cyclin-Dependent Kinase 4/6 Inhibitor in Various Solid Tumors.
Tripathy D, Bardia A, Sellers WR. Tripathy D, et al. Clin Cancer Res. 2017 Jul 1;23(13):3251-3262. doi: 10.1158/1078-0432.CCR-16-3157. Epub 2017 Mar 28. Clin Cancer Res. 2017. PMID: 28351928 Free PMC article. Review.
Mechanism of Action and Clinical Impact of Ribociclib-Letter.
Sorscher S. Sorscher S. Clin Cancer Res. 2017 Sep 15;23(18):5657. doi: 10.1158/1078-0432.CCR-17-1307. Clin Cancer Res. 2017. PMID: 28916618 No abstract available.